{
    "clinical_study": {
        "@rank": "166474", 
        "arm_group": {
            "arm_group_label": "Nonvalvular Atrial Fibrillation patients with risk of Stroke", 
            "description": "Patients undergoing elective total hip replacement arthroplasty or elective total knee replacement arthroplasty and signed on the data release"
        }, 
        "brief_summary": {
            "textblock": "The objective of this regulatory Post-Marketing Surveillance in Korea is to reconfirm the\n      clinical usefulness of Eliquis through collecting, reviewing, identifying and verifying the\n      safety and effectiveness information about Eliquis in general practice"
        }, 
        "brief_title": "Eliquis Regulatory Post Marketing Surveillance", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "NONVALVULAR ATRIAL FIBRILLATION", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u226519 years of age\n\n          -  Adult patients who are diagnosed with nonvalvular atrial fibrillation and are\n             initiating Eliquis anticoagulation therapy for risk reduction of stroke and systemic\n             embolism\n\n          -  Patients with evidence of a personally signed and dated informed consent document\n             indicating that the patient (or a legally acceptable representative) has been\n             informed of all pertinent aspects of the study\n\n        Exclusion Criteria:\n\n          -  Receiving Eliquis treatment for an indication that is not approved in Korea\n\n          -  Contraindicated for the use of Eliquis as described in the Korean label"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Primary care clinic physicians should enroll all adult patients who are diagnosed with\n        nonvalvular atrial fibrillation and who need anticoagulation therapy for risk reduction of\n        stroke and systemic embolism and who are receiving Eliquis 5 mg or 2.5 mg for the first\n        time"
            }
        }, 
        "enrollment": {
            "#text": "3000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01885598", 
            "org_study_id": "CV185-259"
        }, 
        "intervention": {
            "arm_group_label": "Nonvalvular Atrial Fibrillation patients with risk of Stroke", 
            "intervention_name": "Apixaban", 
            "intervention_type": "Drug", 
            "other_name": "Eliquis"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 15, 2013", 
        "number_of_groups": "1", 
        "official_title": "Eliquis (Apixaban) Regulatory Postmarketing Surveillance in Clinical Practice for Stroke Prevention in Nonvalvular Atrial Fibrillation", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Occurrence of stroke, systemic embolism and death", 
            "safety_issue": "Yes", 
            "time_frame": "At each visit (3, 6, 12 and 24 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01885598"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "October 2013"
    }
}